Biotech Partnerships: Types, Structures & How They Work

Why Biotech Partnerships Are Different

Before diving into specific partnership models, it is essential to understand what makes biotech deal dynamics fundamentally different from Big Pharma transactions. These differences shape every aspect of deal structure, negotiation, and governance.

These dynamics mean that biotech partnerships require structures that are fundamentally different from standard pharmaceutical licensing deals. The best deals balance the biotech's need for capital and commercial reach with its need to retain scientific control, strategic optionality, and a fair share of long-term value creation.

The Seven Core Biotech Partnership Models

Biotech partnerships can be organized into seven distinct structural models, each with different risk allocation, economics, governance requirements, and strategic implications.

1. Licensing Partnerships (In-Licensing & Out-Licensing)

The most traditional partnership model: one party licenses rights to develop and/or commercialize an asset in defined territories. The licensor retains ownership of the underlying IP and receives economic consideration (upfronts, milestones, royalties). The licensee takes on development risk and commercial execution in its territories.

For biotechs, licensing partnerships come in two primary flavors:

• Out-licensing: The biotech licenses rights to its asset to a partner (typically a larger pharma company) in exchange for upfront payments, milestones, and royalties. This is the most common biotech partnership model, representing approximately 60% of all biotech deals by volume.
• In-licensing: The biotech acquires rights to an external asset — often from an academic institution, another biotech, or a pharma company divesting non-core assets — to build or complement its pipeline.

Typical economics (out-licensing): Upfronts of $10M-$500M+ (stage-dependent), development milestones of $50M-$2B, commercial milestones of $100M-$3B, and tiered royalties of 5-25% on net sales. For a detailed breakdown, see our cross-border licensing term sheet guide.

Best suited for: Biotechs that need capital to fund other programs, lack commercial capabilities in the licensed territory, or want to de-risk a single-asset company by monetizing geographic rights.

2. Co-Development Agreements

In a co-development partnership, both parties share the costs and risks of clinical development, typically splitting expenses 50/50 (though other ratios are common). In return, both parties share in the commercial upside — either through profit-sharing or through defined territory splits with each party commercializing in its own regions.

Key structural elements:

• Cost sharing: Typically 50/50 for global development costs, with each party funding territory-specific costs (regulatory, commercial) in its own regions
• Governance: Joint development committee (JDC) with defined decision-making authority. Deadlock provisions are critical — who has final say on trial design, regulatory strategy, and label claims?
• Commercialization: Each party commercializes in its territories (e.g., biotech takes US; pharma partner takes ex-US) or a 50/50 profit share in overlapping territories
• Opt-out provisions: Typically, either party can opt out of co-development at defined stage gates, reverting to a traditional license structure with reduced economics

Advantages for biotechs: Retain commercial rights in key markets (typically US), share development risk, access partner's regulatory and development expertise, and capture significantly more long-term value than a traditional out-license.

Risks for biotechs: Requires significant capital commitment (50% of Phase 3 costs can be $200M-$500M+), governance complexity, and the need to build a commercial organization. If the biotech cannot fund its share, it may be forced to opt out at a disadvantageous stage.

Real-world example: The Daiichi Sankyo-AstraZeneca partnership on Enhertu (trastuzumab deruxtecan) is the gold standard for co-development. The companies shared global development costs and co-commercialize worldwide, with Daiichi Sankyo retaining manufacturing and Japan commercial rights. The deal has generated $20B+ in cumulative value.

3. Co-Promotion & Co-Commercialization

Co-promotion involves two companies jointly marketing an approved product in the same territory. Unlike co-development (which covers the R&D phase), co-promotion is a commercial-stage arrangement where both partners deploy sales forces, with revenue or profits shared according to a pre-agreed formula.

Common structures:

• Profit split: Both parties invest in commercialization and split pre-tax profits (e.g., 50/50, 60/40). This is the most aligned structure but requires transparent cost accounting.
• Revenue split: Each party receives a defined percentage of net revenue, regardless of costs invested. Simpler to administer but may create misaligned incentives around investment levels.
• Tiered compensation: The co-promotion partner receives a percentage of incremental revenue above a baseline. This ensures the product owner benefits from base demand while the partner is compensated for incremental contribution.

Best suited for: Biotechs with approved products that need additional commercial reach — particularly in primary care markets that require large sales forces. Also useful when entering a new therapeutic area where the biotech lacks established KOL relationships.

4. Research Collaborations

Research collaborations are early-stage partnerships where a larger company funds research activities at a biotech (or academic institution) to explore novel biology, validate targets, or generate lead compounds. These are the earliest-stage partnerships and carry the highest scientific risk but the lowest financial commitment.

Typical structure:

• Funding: The pharma partner provides $5M-$50M in research funding over 2-5 years, supporting a defined set of research programs
• IP ownership: Jointly generated IP is typically owned by the biotech, with the pharma partner receiving options or rights of first negotiation on resulting clinical candidates
• Option rights: The pharma partner usually has the option to license specific programs that emerge from the collaboration, at pre-negotiated or ROFN terms
• Target exclusivity: The biotech may agree to work exclusively with the partner on defined targets, while retaining freedom to operate on non-overlapping programs

Best suited for: Platform biotechs with broad target applicability (e.g., gene editing companies, AI drug discovery platforms), academic spinouts seeking validation capital, and biotechs with novel biology that needs pharma-scale development capabilities to translate into clinical programs.

5. Platform Technology Deals

Platform deals are among the highest-value biotech partnerships. Rather than licensing a single product, the pharma partner gains access to the biotech's technology platform to develop multiple products. These deals are particularly common in modalities like mRNA, ADCs, gene editing, cell therapy, and AI-driven drug design.

Key structural elements:

• Target nominations: The pharma partner can nominate a defined number of targets (e.g., 5-10) to be developed using the biotech's platform over a defined period
• Exclusivity: Nominated targets are exclusive to the partner; the biotech retains freedom to develop other targets independently or with other partners
• Economics per target: Each nominated target triggers its own license, with upfronts, milestones, and royalties accruing independently. Total deal value is the sum across all targets.
• Platform access fee: A separate upfront payment ($50M-$500M) for access to the platform, distinct from per-target economics
• Technology transfer: In some deals, the pharma partner receives a technology license to use the platform internally, with or without ongoing support from the biotech

Best suited for: Biotechs with differentiated platform technologies that have broad target applicability. The key advantage is economic leverage — a single platform deal can generate economics comparable to licensing 5-10 individual assets, while the biotech retains the platform for its own programs and additional partnerships.

6. Option-to-Acquire (OTA) Agreements

Option-to-acquire deals have emerged as one of the most popular biotech partnership structures since 2023. In an OTA, a larger company makes an upfront investment (equity, research funding, or both) in a biotech and receives the option — but not obligation — to acquire the company or its lead asset at a pre-negotiated price after a defined milestone (typically Phase 2 data).

How OTA deals work:

• Upfront investment: The pharma partner invests $50M-$500M in the biotech through equity purchase, research funding, or a combination
• Option exercise trigger: The option becomes exercisable upon achievement of a defined milestone — typically positive Phase 2 data, regulatory milestone, or a specific time period
• Acquisition price: Pre-negotiated at the time of the initial deal, typically at a premium to the biotech's current valuation. May include fixed price, formula-based pricing, or a premium over trailing VWAP for public biotechs.
• Option window: The partner typically has 60-180 days after the trigger event to exercise the option
• Walk-away rights: If the partner declines to exercise, the biotech retains all IP and is free to pursue other partnerships or independent development

Advantages for biotechs: Immediate capital infusion, validation from a credible partner, defined acquisition premium that rewards the biotech for de-risking, and a built-in exit path. If the partner does not exercise, the biotech has been funded to a more advanced stage and can pursue alternatives at a higher valuation.

Risks for biotechs: The pre-negotiated price may undervalue the asset if clinical data is highly positive. The option can create an "overhang" that deters other potential acquirers. And the biotech may become strategically dependent on the option partner, investing disproportionate management attention in the relationship.

7. Profit-Sharing & Co-Invest Models

Profit-sharing partnerships represent the deepest level of economic alignment between partners. Rather than paying milestones and royalties, the partners share pre-tax profits from the product — typically 50/50 — and correspondingly share all costs of development and commercialization.

Key differences from co-development:

• Profit-sharing extends through commercialization (co-development may revert to a royalty structure post-approval)
• Requires fully transparent P&L reporting and joint decision-making on all cost lines
• Creates deeper organizational integration and governance complexity
• Typically limited to high-conviction programs where both parties see blockbuster potential

Royalty Models vs. Profit-Sharing: Economic Comparison

The choice between a royalty-based and profit-sharing structure has profound implications for the biotech's economics. Here is a simplified comparison for a product achieving $2B in peak annual net sales:

The profit-sharing model generates 50-100% more cumulative economics for the biotech but requires significantly more capital, operational capability, and governance investment. For well-capitalized biotechs with high-conviction assets, profit sharing is the value-maximizing structure. For capital-constrained companies, a royalty-based license with higher upfronts may be the more rational choice.

Partnership Model Comparison Matrix

The following matrix compares all seven partnership models across key dimensions to help executives identify the right structure for their situation.

What Makes Biotech Partnerships Succeed — or Fail

Industry data suggests that approximately 40-50% of biotech partnerships underperform expectations, and 15-20% are terminated prematurely. Understanding the drivers of success and failure is essential for structuring partnerships that deliver value.

Key Success Factors

Common Failure Modes

• Partner shelving: The most feared failure mode — the larger partner deprioritizes the asset in favor of internal programs or competing partnerships. Diligence obligations and anti-shelving provisions are critical contractual protections, but they are difficult to enforce in practice.
• Decision paralysis: Joint committees without clear authority create decision bottlenecks. When the partners disagree on trial design or regulatory strategy, the program stalls. Deadlock resolution mechanisms (casting votes, third-party arbitration, escalation to C-suite) must be defined upfront.
• Misaligned incentives: When one partner has a competing asset in the same therapeutic area, the incentive to maximize the partnered program is compromised. Competitive products clauses and anti-compete provisions help but do not eliminate this risk.
• Integration failure: In co-development and profit-sharing partnerships, the day-to-day integration of two organizations — data sharing, regulatory submissions, manufacturing coordination — is operationally complex. Teams that are not set up for cross-organizational collaboration will struggle regardless of how well the deal is structured.
• Change of control disruption: When one partner is acquired by a third party, the partnership dynamic shifts. The new owner may have different priorities, competing programs, or reduced commitment. Change-of-control provisions — including termination rights and IP reversion — are essential contractual protections.

Special Considerations: Academic Spinout Partnerships

A significant number of biotech partnerships involve academic spinouts — companies formed around technology developed at universities or research institutions. These partnerships have unique structural considerations:

• IP ownership complexity: Academic IP is often encumbered with march-in rights (under the Bayh-Dole Act in the US), inventor royalty obligations, and field-of-use restrictions. The biotech's license from the university must be broad enough to support the proposed partnership.
• Inventor involvement: Academic founders often retain advisory roles and may have contractual rights that affect the partnership (publication rights, research exemptions). Partners must understand these dynamics.
• Technology maturity: Academic spinout technology is typically at an earlier stage than pharma-ready assets. Partnerships must account for the additional de-risking required — proof-of-concept studies, assay development, formulation optimization — before clinical development can begin.
• Valuation challenges: Preclinical academic-stage assets are inherently difficult to value. rNPV models are unreliable at this stage because probability of success and development cost estimates have wide confidence intervals. Partners often use comparable deal analysis and platform valuation methodologies instead.

Cross-Border Biotech Partnership Considerations

An increasing proportion of biotech partnerships are cross-border — particularly deals involving Chinese biotechs licensing to Western partners (or vice versa), European biotechs partnering with US companies, and Japanese pharma companies in-licensing from global biotechs. Cross-border deals add layers of complexity:

• Regulatory divergence: Different markets have different clinical development requirements, approval timelines, and post-marketing obligations. The partnership must define who is responsible for regulatory strategy in each territory and how conflicting regulatory feedback is managed.
• Transfer pricing and tax: Cross-border license payments trigger transfer pricing considerations. The structure of upfronts, milestones, and royalties must be tax-efficient for both parties while complying with arm's-length principles.
• Geopolitical risk: The BIOSECURE Act, export controls, and shifting geopolitical dynamics increasingly affect cross-border biotech partnerships. Deals involving Chinese companies must consider potential regulatory restrictions and supply chain implications. See our analysis of the BIOSECURE Act's impact on pharma for details.
• Cultural negotiation dynamics: Negotiation styles, decision-making processes, and relationship expectations differ significantly across cultures. Cross-border partnerships require advisors who understand both sides and can bridge communication gaps.
• Currency and payment: Multi-year milestone and royalty streams denominated in different currencies create exposure that must be managed through the deal structure or hedging strategies.

Choosing the Right Partnership Model: A Decision Framework

The optimal partnership structure depends on the intersection of several factors. Here is a practical framework for making the decision:

Frequently Asked Questions